X4 Pharmaceuticals, Inc. (XFOR)
3.73
-0.12
(-3.12%)
USD |
NASDAQ |
Jun 10, 16:00
3.72
-0.01
(-0.27%)
After-Hours: 20:00
X4 Pharmaceuticals Shareholders Equity (Quarterly) : 168.45M for March 31, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 168.45M |
| December 31, 2025 | 186.29M |
| September 30, 2025 | 61.62M |
| June 30, 2025 | 3.971M |
| March 31, 2025 | 22.94M |
| December 31, 2024 | 22.15M |
| September 30, 2024 | 59.62M |
| June 30, 2024 | 94.45M |
| March 31, 2024 | 1.036M |
| December 31, 2023 | 51.10M |
| September 30, 2023 | 67.59M |
| June 30, 2023 | 67.54M |
| March 31, 2023 | 51.68M |
| December 31, 2022 | 74.05M |
| September 30, 2022 | 61.85M |
| June 30, 2022 | 30.07M |
| March 31, 2022 | 49.71M |
| December 31, 2021 | 64.41M |
| September 30, 2021 | 68.68M |
| Date | Value |
|---|---|
| June 30, 2021 | 89.21M |
| March 31, 2021 | 106.94M |
| December 31, 2020 | 72.80M |
| September 30, 2020 | 89.71M |
| June 30, 2020 | 104.88M |
| March 31, 2020 | 118.79M |
| December 31, 2019 | 129.22M |
| September 30, 2019 | 79.11M |
| June 30, 2019 | 96.17M |
| March 31, 2019 | 29.44M |
| December 31, 2018 | -11.68M |
| September 30, 2018 | 27.90M |
| June 30, 2018 | 37.76M |
| March 31, 2018 | 48.42M |
| December 31, 2017 | 58.71M |
| September 30, 2017 | 11.57M |
| June 30, 2017 | 18.11M |
| March 31, 2017 | -22.01M |
| December 31, 2016 | -16.72M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Kyverna Therapeutics, Inc. | 195.58M |
| Arrowhead Pharmaceuticals, Inc. | 613.98M |
| Oncolytics Biotech, Inc. | -5.13M |
| Sangamo Therapeutics, Inc. | -18.96M |
| Sarepta Therapeutics, Inc. | 1.505B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 270.28M |
| Total Liabilities (Quarterly) | 101.83M |
| Debt to Equity Ratio | 0.4586 |
| Current Ratio | 10.18 |
| Net Debt Paydown Yield | 0.04% |